Jeremy Hayden Sells 12,733 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Posted by George Bondi on Jul 8th, 2026

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) insider Jeremy Hayden sold 12,733 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.51, for a total value of $70,158.83. Following the completion of the sale, the insider owned 357,037 shares of the company’s stock, valued at approximately $1,967,273.87. This trade represents a 3.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Sight Sciences Price Performance

NASDAQ:SGHT opened at $5.35 on Wednesday. The company has a quick ratio of 5.48, a current ratio of 5.86 and a debt-to-equity ratio of 0.68. The business’s 50-day moving average price is $4.97 and its 200 day moving average price is $5.29. Sight Sciences, Inc. has a 52-week low of $3.11 and a 52-week high of $9.24. The firm has a market cap of $291.09 million, a P/E ratio of -7.54 and a beta of 2.38.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05). The business had revenue of $19.70 million for the quarter, compared to the consensus estimate of $18.46 million. Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. As a group, sell-side analysts predict that Sight Sciences, Inc. will post -0.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on SGHT. Citigroup increased their price objective on Sight Sciences from $4.35 to $5.15 and gave the company a “neutral” rating in a research report on Thursday, May 28th. Weiss Ratings lowered Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.14.

Get Our Latest Report on SGHT

Sight Sciences News Roundup

Here are the key news stories impacting Sight Sciences this week:

Negative Sentiment: CEO Paul Badawi sold 28,684 shares, the largest disclosed insider transaction in the batch, which may suggest reduced insider confidence. Sight Sciences (NASDAQ:SGHT) CEO Paul Badawi Sells 28,684 Shares of Stock
Negative Sentiment: CFO James Rodberg sold 6,902 shares, adding to the leadership-level selling pressure. Sight Sciences (NASDAQ:SGHT) CFO Sells 6,902 Shares
Negative Sentiment: CTO David Badawi, EVP Brenton Taylor, and insider Jeremy B. Hayden also sold shares, reinforcing the pattern of insider reductions across the company. Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells $40,873.18 in Stock Sight Sciences (NASDAQ:SGHT) EVP Sells $15,333.18 in Stock

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its stake in Sight Sciences by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after acquiring an additional 3,785 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after acquiring an additional 2,875 shares in the last quarter. Diversified Trust Co acquired a new position in shares of Sight Sciences in the 1st quarter valued at about $51,000. XTX Topco Ltd acquired a new position in shares of Sight Sciences in the 2nd quarter valued at about $67,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in Sight Sciences during the fourth quarter valued at approximately $81,000. 55.51% of the stock is owned by institutional investors and hedge funds.

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.